SI1381346T1 - Farmacevtski sestavki, ki vsebujejo formoterol - Google Patents

Farmacevtski sestavki, ki vsebujejo formoterol

Info

Publication number
SI1381346T1
SI1381346T1 SI200231067T SI200231067T SI1381346T1 SI 1381346 T1 SI1381346 T1 SI 1381346T1 SI 200231067 T SI200231067 T SI 200231067T SI 200231067 T SI200231067 T SI 200231067T SI 1381346 T1 SI1381346 T1 SI 1381346T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical compositions
compositions containing
containing formoterol
formoterol
pharmaceutical
Prior art date
Application number
SI200231067T
Other languages
English (en)
Inventor
Partha S. Banerjee
Stephen Pham
Imtiaz A. Chaudry
Original Assignee
Mylan Specialty L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1381346(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Specialty L.P. filed Critical Mylan Specialty L.P.
Publication of SI1381346T1 publication Critical patent/SI1381346T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200231067T 2001-04-17 2002-02-28 Farmacevtski sestavki, ki vsebujejo formoterol SI1381346T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28460601P 2001-04-17 2001-04-17
US09/887,281 US6667344B2 (en) 2001-04-17 2001-06-22 Bronchodilating compositions and methods
EP02709742.7A EP1381346B1 (en) 2001-04-17 2002-02-28 Pharmaceutical compositions containing formoterol
PCT/US2002/006240 WO2002083079A2 (en) 2001-04-17 2002-02-28 Aerosol compositions containing formoterol for delivery to the lungs via nebulization

Publications (1)

Publication Number Publication Date
SI1381346T1 true SI1381346T1 (sl) 2016-03-31

Family

ID=26962700

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200231067T SI1381346T1 (sl) 2001-04-17 2002-02-28 Farmacevtski sestavki, ki vsebujejo formoterol

Country Status (9)

Country Link
US (2) US6667344B2 (sl)
EP (1) EP1381346B1 (sl)
JP (4) JP2004532217A (sl)
AU (1) AU2002244211B2 (sl)
CA (1) CA2438544C (sl)
ES (1) ES2554476T3 (sl)
PT (1) PT1381346E (sl)
SI (1) SI1381346T1 (sl)
WO (1) WO2002083079A2 (sl)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20020187099A1 (en) * 2001-05-16 2002-12-12 Rajesh Manchanda Stabilization of radionuclide-containing compositions
WO2002096422A2 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
AU2003273328A1 (en) * 2002-09-18 2004-04-08 Infineon Technologies Ag Nitride and polysilicon interface with titanium layer
US20040110845A1 (en) * 2002-12-06 2004-06-10 Ramana Malladi Stabilized albuterol compositions and method of preparation thereof
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
DE602004028585D1 (de) * 2003-03-15 2010-09-23 Brin Tech Internat Ltd Verpackung für Arzneimittel
SE0301260D0 (sv) * 2003-04-29 2003-04-29 Astrazeneca Ab Novel equipment
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
JP5564158B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050042176A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a steroid
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005040257A1 (en) 2003-10-21 2005-05-06 E.I. Dupont De Nemours And Company Ethylene copolymer modified oriented polyester films, tapes, fibers and nonwoven textiles
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
WO2005074918A1 (en) * 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
WO2005097095A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JP2008502699A (ja) * 2004-06-14 2008-01-31 セプラコール・インコーポレイテッド 肺疾患治療方法、及びそのための組成物
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
KR20070102659A (ko) * 2004-09-09 2007-10-19 씨아이피엘에이 엘티디. 베타작용제의 이성체 및 항-콜린제를 포함하는 약제학적조성물
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
EA016072B1 (ru) * 2005-05-18 2012-01-30 Палметрикс Инк. Применение состава соли кальция для изменения биофизических свойств слизистой оболочки
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
ES2332290T3 (es) * 2005-08-01 2010-02-01 Chiesi Farmaceutici S.P.A. Formulaciones farmaceuticas que comprenden un agonista de beta2 de accion prolongada para su administracion mediante nebulizacion.
DK1928821T3 (da) * 2005-09-21 2009-03-16 Pfizer Ltd Carboxamidderivater som muscarinreceptorantagonister
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
JP5107933B2 (ja) 2005-12-21 2012-12-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
WO2007137206A2 (en) * 2006-05-18 2007-11-29 Tika Läkemedel Ab Unit dose formulations comprising an inhalable solution of albuterol
WO2007140285A2 (en) * 2006-05-26 2007-12-06 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
EP1925296A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein neues Anticholinergikum
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
EP2237788A4 (en) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP3184099A1 (en) 2009-03-26 2017-06-28 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN101544386B (zh) * 2009-04-29 2011-01-05 余荣华 一种生产硝酸钾并联产氯化铵和硝酸铵的方法
TWI695723B (zh) * 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
UA113832C2 (xx) 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
KR101727085B1 (ko) * 2010-01-21 2017-04-14 아프레아 에이비 과증식성 질환, 자가면역 질환 및 심장 질환을 치료하기 위한 3-퀴뉴클리디논을 포함하는 수용액
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
WO2012044736A1 (en) 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
CN107224427A (zh) * 2013-07-01 2017-10-03 成都苑东生物制药股份有限公司 一种格隆溴铵注射液组合物及其制备方法
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
CN107362140A (zh) * 2016-05-11 2017-11-21 广东东阳光药业有限公司 喷雾剂以及喷雾组件
BR112019007259A2 (pt) * 2016-10-14 2019-07-02 Glenmark Specialty S.A. recipiente de câmara dupla adequado para uso com um nebulizador e pré-carregado com uma composição nebulizável, kit, composição nebulizável, solução nebulizável aquosa, método para administrar de tiotrópio e formoterol a um paciente com necessidade do mesmo e método para preparar um nebulizador
CN108853011B (zh) * 2018-06-13 2021-01-29 北京华润高科天然药物有限公司 一种葡萄糖酸钙-l-乳酸钙口服液及其制备方法
WO2020122928A1 (en) * 2018-12-14 2020-06-18 National Taiwan University A stable cardioplegic solution for cardiac surgery
CN112870172B (zh) * 2019-11-29 2022-09-13 北京福元医药股份有限公司 一种孟鲁司特钠药物制剂
US20210275449A1 (en) * 2020-03-01 2021-09-09 Cai Gu Huang Inhalable Formulation of a Solution Containing Glycopyrronium Bromide
CN112326808A (zh) * 2020-09-24 2021-02-05 南京斯泰尔医药科技有限公司 一种测定注射液中焦亚硫酸钠含量的方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2366625C2 (sl) 1972-02-05 1988-06-09 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (sl) 1972-05-19 1975-08-18 Bofors Ab
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8825892D0 (en) 1988-11-04 1988-12-07 Fisons Plc Pharmaceutical composition
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
DE69130762T2 (de) 1990-09-18 1999-09-09 Rodime Plc Digitale servosteuerung für ein plattenlaufwerk
US5785952A (en) 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
JP3026841B2 (ja) 1991-12-12 2000-03-27 グラクソ、グループ、リミテッド 医 薬
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
DE69232462T2 (de) * 1991-12-18 2002-10-10 Astrazeneca Ab Formoterol und budesonide enthaltende zusammensetzung
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5647347A (en) 1994-10-21 1997-07-15 Glaxo Wellcome Inc. Medicament carrier for dry powder inhalator
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
ATE236617T1 (de) 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DZ1965A1 (fr) 1995-02-06 2002-07-17 Astra Ab Composition pharmaceutique nouvelle.
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6041777A (en) 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US5733526A (en) 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
US5753218A (en) 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
CN1149076C (zh) 1997-03-20 2004-05-12 先灵公司 粉末附聚物的制备方法
WO1999000134A1 (en) 1997-06-27 1999-01-07 Astra Aktiebolag (Publ) New combination of antiasthma medicaments
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE215820T1 (de) * 1997-10-08 2002-04-15 Sepracor Inc Dosierungsform zur verabreichung von aerosolen
US5972327A (en) 1997-10-22 1999-10-26 Lin; Matthew M. Method of treating allergic rhinitis by delivering medication via the nasal vestibules
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
WO1999040939A1 (en) 1998-02-10 1999-08-19 Cangene Corporation Method for the prevention and treatment of a type i hypersensitivity disorder
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
US5993782A (en) 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
KR100445146B1 (ko) 1998-05-27 2004-08-18 유로-셀띠끄 소시에떼 아노님 항염증용 제제, 특히 하부호흡기의 창상치료 촉진용 약제및/또는 소독 약제
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US5965622A (en) 1998-06-23 1999-10-12 Sepracor Inc. Desformoterol and process for its preparation
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE59911149D1 (de) 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
PT1102579E (pt) 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
US6112924A (en) 1998-09-10 2000-09-05 Bcb Usa, Inc. Container with base having cylindrical legs with circular feet
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
ES2178479T3 (es) * 1998-10-17 2002-12-16 Boehringer Ingelheim Pharma Concentrado de principio activo con formoterol, apto para el almacenamiento.
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
IT1303692B1 (it) 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
CA2317999C (en) 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
DE19947235A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9903995D0 (sv) 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
US20030026766A1 (en) 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
DE60203652T2 (de) 2001-01-31 2005-09-08 Pfizer Products Inc., Groton Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyme
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof

Also Published As

Publication number Publication date
WO2002083079A2 (en) 2002-10-24
CA2438544C (en) 2010-11-09
EP1381346B1 (en) 2015-11-18
JP2004532217A (ja) 2004-10-21
PT1381346E (pt) 2016-02-04
AU2002244211B2 (en) 2007-07-05
EP1381346A2 (en) 2004-01-21
CA2438544A1 (en) 2002-10-24
JP2013155208A (ja) 2013-08-15
WO2002083079A3 (en) 2003-02-13
WO2002083079A9 (en) 2003-04-10
US6667344B2 (en) 2003-12-23
ES2554476T3 (es) 2015-12-21
US20020151598A1 (en) 2002-10-17
JP6214925B2 (ja) 2017-10-18
JP2015178506A (ja) 2015-10-08
US20020151597A1 (en) 2002-10-17
US6814953B2 (en) 2004-11-09
JP2009046490A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
SI1381346T1 (sl) Farmacevtski sestavki, ki vsebujejo formoterol
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
IL162581A0 (en) Pharmaceutical compositions containing corticosteroids
EP1407785A4 (en) MEDICAL COMPOSITIONS
HK1065944A1 (en) Medicinal compositions
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
GB0111597D0 (en) Pharmaceutical compositions
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
EG24078A (en) Liquid pharmaceutical composition
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
HK1065257A1 (en) Medicinal composition
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
GB0129117D0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
EP1404303A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN
PL370037A1 (en) Pharmaceutical composition
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
HUP0302531A3 (en) Pharmaceutical compositions containing citalopram
GB2382302B (en) Pharmaceutical compositions
GB0114746D0 (en) Medicinal composition
IL157411A0 (en) Pharmaceutical composition